Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Atropine sulfate monohydrate acts in the eye to block the action of acetylcholine, relaxing the cholinergically innervated sphincter muscle of the iris.”
“A half-life of 4 hours has been reported.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Clinical summary for prescribers — atropine (ophthalmic)
Atropine sulfate monohydrate is a belladonna alkaloid (tertiary amine) used in the eye to produce pupillary dilation and paralysis of accommodation. It acts by blocking acetylcholine at the cholinergically innervated sphincter muscle of the iris, relaxing the sphincter and supporting cycloplegia/mydriasis. Reported half-life is approximately 2 hours, with a 4-hour half-life also reported.
Prescribing frame: Use atropine for its indicated ophthalmic effects—pupillary dilation and accommodation paralysis—after confirming the indication and assessing angle-closure risk. It is contraindicated in angle-closure glaucoma or suspected angle-closure glaucoma; in glaucoma-susceptible patients, estimate anterior chamber angle depth before starting therapy. It is also contraindicated in patients with hypersensitivity to any ingredient.
Counsel/monitor for common effects: blurred vision, local irritation, follicular conjunctivitis, vascular congestion, and oedema.
Recognise serious adverse effects: severe systemic reactions may present with hypotension and progressive respiratory depression; also watch for cardiac arrhythmias (e.g., atrial fibrillation), fever, mental aberration with loss of neuromuscular coordination, and abdominal distension in infants.
Prescriber takeaway: Atropine ophthalmic is effective for dilation and cycloplegia, but prescribers should screen for angle-closure risk and hypersensitivity, counsel on blurred vision/local irritation, and remain alert to uncommon but serious systemic anticholinergic toxicity.